N-1-leucyl-doxorubicin and vinblastine-isoleucinate can be considered as relatively non-toxic prodrugs from doxorubicin and vinblastine, respectively. A comparative analysis was carried out of the anti-tumour activity of the four compounds as well as vintriptol in four human ovarian cancer xenografts different in histology, growth rate and chemosensitivity. Injections were given i.v. weekly twice into mice bearing well-established s.c. tumours. At equitoxic doses, the amount of drug administered for N-l-leucyldoxorubicin and vinblastine-isoleucinate was respectively 3-fold and 2-fold higher than the doses of the parent compound. N-l-leucyl-doxorubicin induced a growth inhibition > 50% in three out of four human ovarian cancer lines. The anti-tumour effects obtained were significantly better (P <0.01) than in the case of doxorubicin. Vinblastine-isoleucinate studied in two of these lines could induce a growth inhibition of > 50%. This prodrug appeared slightly less effective than vinblastine. Insignificant growth inhibition (<50%) was obtained by vintriptol.
The synthesis of relatively non-toxic prodrugs of conventional cytostatic agents is another approach to limit sideeffects. This concept is based on the conversion of the prodrug into its active form by an enzyme, which is preferably exclusive for the target tissue. Theoretically, the prodrug can be given in large doses enabling high concentrations of free drug available at the tumour site. Several examples of prodrugs are found in the purine and pyrimidine analogues, which substitute for natural nucleotides and inhibit the formation of nucleic acids. There is evidence, that these antimetabolites have some selectivity for rapidly dividing cells, but this may reflect the greater metabolic demand of such cells rather than selective activation (Waller et al., 1989) .
In 1980, the group of Trouet (Baurain et al., 1980; Masquelier et al., 1980a) have selected leucyl-derivatives for further preclinical development, because these prodrugs were most sensitive to enzymatic hydrolysis as compared to other amino acid derivatives. N-l-leucyl-doxorubicin (leu-doxorubicin) and vinblastine-isoleucinate (vinblastine-leu) (Boven et al., 1990 ).
Treatment and evaluation
All compounds were provided by Medgenix Group, Fleurus, Belgium. N-l-leucyl-doxorubicin contains one I-leucine amino acid linked to the amino group of doxorubicin as previously published for leu-daunomycin (Masquelier et al., 1980a) . The drug was dissolved in water at a concentration of 20 mg ml-l immediately before use. Doxorubicin was dissolved in water at a concentration of 2 mg ml-1. Vinblastineisoleucinate is a vinblastine-23-oyl amino acid derivative, which possesses an isoleucinate ethyl ester (Bhushana Rao et al., 1985) . The drug was dissolved in glucose 5% at a concentration of 2 mg ml-' immediately before use. Vintriptol (4-deacetyl-3-L-ethyltryptophyl vincaleukoblastine dimethane sulphonate) has a tryptophan ethyl ester linked to the amino ester of the vinblastine-23-oyl moiety (Bhushana Rao et al., 1985) . This drug was dissolved in glucose 5% at a concentration of 10 mg ml-, whereas the concentration of vinblastine sulphate in glucose 5% was 1 mg ml-'.
The methodology of the therapeutic experiments was derived from the guidelines reported earlier for preclinical phase II drug screening in human tumour xenografts (Boven et al., 1988) Various doses were given to groups of 4-6 animals each and mean body weight loss was recorded from daily measurements. If required, the MTD was adjusted in tumour-bearing mice or in experiments performed in another nude mouse strain.
Doxorubicin was administered at a dose of 8 mg kg-' as has been previously published (Boven et al., 1988; Boven et al., 1990) . For leu-doxorubicin it was found that doses of 32-40 mg kg-' induced a mean weight loss of up to 6-7%, but irreversible cachexia after the third week of treatment comprised the evaluability of anti-tumour efficacy. This was reason to reduce the dose to 28 mg kg-' in tumour-bearing mice, which appeared to be well tolerated. Doses for vinblastine and vinblastine-leu were 6 mg kgand 12 mg kg-1, respectively, which were similar to the MTDs in other testing laboratories (Hendriks et al., 1992) . However, in our nude mouse strain vintriptol 60 mg kg-' induced a mean weight loss of 13%, which was 7% at a dose of 50 mg kg-'. Therefore it was decided to select the 50 mg kg-' dose for the therapeutic experiments, which was slightly lower than given in other testing laboratories (Hendriks et al., 1992) .
To give insight in the toxicity in the ultimate experiments residual weight loss measured at day 14 after the start of treatment and toxic deaths within two weeks after the last injection are indicated in Table I . In general, recovery from weight loss was completed by day 21.
Anti-tumour efficacy
The anti-tumour effects of doxorubicin and leu-doxorubicin were compared in four human ovarian cancer lines (Table I and Figure 1) (Boven et al., 1985a (Boven et al., , 1985b (Boven et al., , 1990 ). We found leu-doxorubicin better effective than doxorubicin, vinblastine-leu was slightly less effective than vinblastine, and vintriptol was ineffective in the human ovarian cancer xenografts selected for the present experiments.
Leu-doxorubicin has been shown earlier to have a more favourable toxicity and anti-tumour activity profile as compared to the parent compound. In this respect, the prodrug did induce less cardiomyopathy after chronic treatment in rabbits, while 3-3.5 times the doxorubicin dose could be administered (Jaenke et al., 1980) . This reduced cardiomyopathy appeared attributable to a lower accumulation of active drug in heart tissue, which was also demonstrated in mice (Deprez-De Campeneere et at., 1982) . In L1210 leu- of% f% kemia grown s.c. in mice leu-doxorubicin was superior to doxorubicin as expressed by the considerable increase in life-span (Baurain et al., 1980) . These promising characteristics led to extensive efforts to elucidate the mechanism of prodrug activation. Cellular pharmacology of leu-doxorubicin indicated hydrolytic enzymes found within lysosomes, such as cathepsin B and N-acetyl-i-glucosaminidase, to be responsible for the release of active drug (Masquelier et al., 1980b) . At equitoxic doses in human tumour-bearing nude mice, leu-doxorubicin could be given in a 3-fold higher dose than doxorubicin and was found again better effective than the parent compound. This suggests, that human tumour tissue may be the major site for activation of this prodrug. Hydrolytic enzymes known to occur in high concentrations in human tumour cells are cathepsins. These cysteine proteases can be measured in tissue cytosol and elevated concentrations have been correlated with malignancy or even prognosis (Maciewicz et al., 1989; Thorpe et al., 1989) . Cell death or secretion of these proteases may result in enzyme activity in the pericellular space. Recently, leu-doxorubicin has entered clinical trials in cancer patients and the MTD was indeed 3-fold higher than that of the parent compound (Tresca et al., 1991) . The amount of free drug in the circulation after leu-doxorubicin administration to patients was 4-fold lower than for an equimolar dose of the parent compound (De Jong et al., 1991) .
From the vinblastine-23-oyl amino acid derivatives, both vinblastine-leu and vintriptol were found to induce a higher increase in life-span of mice implanted i.v. with P388 or L1210 leukaemia as compared to vinblastine (Bhushana Rao et al., 1985) . In our human ovarian cancer xenografts, however, none of the drugs was superior to vinblastine. For vinblastine-leu, an explanation may be that only a 2-fold higher dose than that for the parent compound could be given. Several mechanisms may explain the differential efficacy observed with leu-doxorubicin and vinblastine-leu in the same human ovarian cancer xenografts, such as differences in pharmacokinetics, tumour tissue distribution, prodrug activation at the tumour site, or the cellular uptake rate of the activated drugs. These questions should be addressed in further experiments to gain better insight in the potential clinical value of leucyl derivatives for use as prodrugs. For vintriptol, a recent phase I clinical trial showed that myelosuppression was the dose-limiting factor, rather than neurotoxicity (Oosterkamp et al., 1991) . Unfortunately, preliminary data from a broad phase II trial have not indicated tumour types to be responsive to the drug (Ten Bokkel Huinink et al., 1990) .
The development of prodrugs of conventional cytostatic agents remains an interesting area in the search of anticancer drugs with a higher therapeutic index. Human tumour xenografts may add valuable information on the anti-tumour activity of these prodrugs to be expected in the clinic. In this respect, a phase II trial in ovarian cancer patients is awaited to demonstrate the potential superiority of leu-doxorubicin in terms of improvement of efficacy and reduction of cardiotoxicity.
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